Trial result ·
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This study looked at blood and urine copper tests in Wilson disease. It used data from an earlier trial called CHELATE. In that trial, 77 people with stable disease took penicillamine. After 12 weeks, 53 people were picked by chance for their next drug. Some kept taking penicillamine, and others switched to trientine. The team looked back at their test results up to week 60. They measured blood copper that was not bound to ceruloplasmin, using newer methods. They also measured copper in urine over 24 hours.
What they found
In 32 people whose dose stayed the same, both blood copper tests went down. The authors think people took their drugs more reliably during the trial. Urine copper fell after the switch to trientine. It fell slowly in the penicillamine group. Test values did not settle until week 60. Urine copper varied the most from visit to visit. The team also looked at 45 people who reached week 60. In them, lower blood copper went with steadier ALT and AST. These people also had higher, steadier albumin and protein in the blood. No nerve changes were seen, and no one ran low on copper.
What it means for patients
The authors say the newer blood copper tests could help guide treatment. This applies to people on long-term treatment for Wilson disease. They say target levels still need to be set. They think these targets might include values below the usual normal range. Changes after a dose change may take 6-12 months to show. The authors say repeated tests may be needed for that reason. They also question using urine copper to guide doses in stable disease.
Why it is not certain yet
This was a look back at data from an earlier trial. Only 45 people completed the trial up to week 60. Test results varied a lot from visit to visit. The authors say more studies are needed on dose changes and missed doses. They also want to know if fixed sampling rules can cut this variation.
Source
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease.
PubMed · PMID 41831608We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Wilson disease publications